A Multiple Dose Trial Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-04457845 in Healthy Volunteers

Phase 1

Completed

• Conditions: Acute Pain; Chronic Pain
• Interventions: Drug: PF-04457845, FAAH inhibitor

• Registration Number: NCT00836082
• Lead Sponsor: Pfizer

Brief Summary

To determine if PF-04457845 at doses of 0.5mg, 1mg, 4mg, and 8 mg given once daily for 14 days will be safe and well tolerated in healthy volunteers. To determine the effect on food on PF-04457845 pharmacokinetics and safety following administration of single doses of 4mg and 8mg.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2009-01-12
• Study Start: 2009-02
• Study First Submitted QC: 2009-02-03
• Study First Posted: 2009-02-04
• Primary Completion: 2009-07
• Study Completion: 2009-07
• Status Verified: 2009-08
• Last Update Submitted: 2009-08-05
• Last Update Posted: 2009-08-06

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 41

Inclusion Criteria

• Healthy male and/or female subjects (of non childbearing potential) between the ages of 18 and 55 years, inclusive (Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12-lead ECG and clinical laboratory tests).
• Body Mass Index (BMI) of approximately 18 to 30 kg/m2; and a total body weight >50 kg (110 lbs).
• Evidence of a personally signed and dated informed consent document indicating that the subject (or a legally acceptable representative) has been informed of all pertinent aspects of the study.
• Subjects who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.

Exclusion Criteria

• Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular (including hyperlipidemia), pancreatic, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).
• History of febrile illness within 5 days prior to the first dose.
• Any condition possibly affecting drug absorption (eg, gastrectomy).
• A positive urine drug screen.
• History of regular alcohol consumption exceeding 14 drinks/week for females or 21 drinks/week for men (1 drink = 5 ounces (150 mL) of wine or 12 ounces (360 mL) of beer or 1.5 ounces (45 mL) of hard liquor) within 6 months of screening.
• Treatment with an investigational drug within 30 days ( or as determined by the local requirement, whichever is longer) or 5 half-lives preceding the first dose of study medication.
• 12-lead ECG demonstrating QTc >450 msec at screening. If QTc exceeds 450msec, the ECG should be repeated two more times and the average of the three QTc values should be used to determine the subject's eligibility.
• Females of childbearing potential.
• Use of prescription or nonprescription drugs, and dietary supplements within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study medication. Herbal supplements and hormonal replacement therapy must be discontinued 28 days prior to the first dose of study medication. As an exception, ibuprofen may be used at doses of up to 1800 mg/day with food. Limited use of non-prescription medications that are not believed to affect subject safety or overall results of the study may be permitted on a case -by-case basis following approval by the sponsor.
• Unwillingness to refrain from consumption of grapefruit or grapefruit/pomelo containing products within 7 days prior to the first dose of study medication until the completion of the follow-up visit.
• Blood donation of approximately 1 pint (500 mL) within 56 days prior to dosing.
• Unwilling or unable to comply with the Lifestyle guidelines described in this protocol.
• Subject is the Investigator or sub-Investigator. research assistant, pharmacist, study coordinator, other staff, or a relative of study personnel directly involved with the conduct of the study.
• Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.
• The use of marijuana (or other illicit drugs) within 30 days of randomization.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Cohort 4 (N=10)	PF-04457845, FAAH inhibitor	Placebo-controlled, escalating multiple doses of 8mg per day for 14 days.
Cohort 1 (N=10)	PF-04457845, FAAH inhibitor	Placebo-controlled, escalating multiple doses of 0.5mg per day for 14 days.
Cohort 2 (N=10)	PF-04457845, FAAH inhibitor	Placebo-controlled, escalating multiple doses of 1mg per day for 14 days.
Cohort 3 (N=10)	PF-04457845, FAAH inhibitor	Placebo-controlled, escalating multiple doses of 4mg per day for 14 days.

Primary Outcome Measures

Name	Time	Method
To characterize the multiple-dose pharmacokinetics of PF-04457845.	14 Days
To characterize the relationship between PF-04457845 and the level of anandamide and level of FAAH enzyme inhibition in healthy adult volunteers following multiple dosing.	14 Days
To evaluate the safety and tolerability of multiple oral doses of PF-04457845.	14 Days
To determine the effect on food on PF-04457845 pharmacokinetics following administration of single doses of 4mg and 8mg.	7-14 Days
To determine the effect on food on PF-04457845 safety following administration of single doses of 4mg and 8mg.	7-14 Days

Secondary Outcome Measures

Name	Time	Method
CogState/GMLT	14 Days
Telemetry	14 Days
Neurologic Exam	14 Days

Trial Locations

Locations (1)

Pfizer Investigational Site; 🇸🇬 Singapore, Singapore